Mn Services Vermogensbeheer B.V. Sells 2,000 Shares of Insulet Co. (NASDAQ:PODD)

Mn Services Vermogensbeheer B.V. decreased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 7.3% in the 1st quarter, HoldingsChannel.com reports. The fund owned 25,400 shares of the medical instruments supplier’s stock after selling 2,000 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Insulet were worth $6,670,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. Empowered Funds LLC raised its position in shares of Insulet by 357.4% during the 4th quarter. Empowered Funds LLC now owns 4,327 shares of the medical instruments supplier’s stock valued at $1,130,000 after acquiring an additional 3,381 shares during the last quarter. Asset Management One Co. Ltd. raised its position in shares of Insulet by 2.3% during the 4th quarter. Asset Management One Co. Ltd. now owns 26,766 shares of the medical instruments supplier’s stock valued at $7,096,000 after acquiring an additional 605 shares during the last quarter. Vontobel Holding Ltd. raised its position in shares of Insulet by 4.3% during the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier’s stock valued at $633,000 after acquiring an additional 100 shares during the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Insulet in the 4th quarter valued at $208,000. Finally, Congress Asset Management Co. increased its position in shares of Insulet by 17.2% in the 4th quarter. Congress Asset Management Co. now owns 65,523 shares of the medical instruments supplier’s stock valued at $17,106,000 after buying an additional 9,623 shares in the last quarter.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now owns 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Insulet Price Performance

PODD stock opened at $306.59 on Tuesday. The stock has a 50-day moving average price of $288.34 and a two-hundred day moving average price of $275.34. The stock has a market cap of $21.58 billion, a PE ratio of 52.95, a price-to-earnings-growth ratio of 3.62 and a beta of 1.37. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 1 year low of $173.00 and a 1 year high of $329.33.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same period in the prior year, the business posted $0.73 EPS. The company’s quarterly revenue was up 28.8% on a year-over-year basis. Equities analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Royal Bank of Canada assumed coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Oppenheimer upped their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Raymond James restated an “outperform” rating and issued a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Piper Sandler upped their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, Barclays upped their price objective on shares of Insulet from $234.00 to $266.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 30th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $321.00.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.